Loading...

SABS SAB BIOTHERAPEUTICS INC Product Launches 8-K Filing

SB B

SBS

SAB BIOTHERAPEUTICS INC

(SABS)

2026 8-K

Manufacturing Agreement

Stock Offering Alert

Clinical Trial Update

Corporate Presentation Update

Board Appointments

New Offering Program

Board Resignations

Stockholder Meeting Results

Equity Investments

Lease Agreement

Clinical Trial Results

Conference Update

Appointment of CFO

Annual Meeting of Stockholders

Appointment of Interim CFO

FDA Clearance for Type 1 Di...

Appointment of Dr. Jay S. S...

Regulation FD Disclosure

Financial Results Announcement

Executive Employment Agreem...

Appointment of CEO

Equity Offering

Compliance regained with Na...

Presentation Update

Reverse Stock Split

Amendment to Articles of In...

Appointment of Director

Amendment to Form 8-K/A

Appointment of CFO

Securities Purchase Agreement

Engagement of EisnerAmper LLP

Accounting Firm Resignation

Presentation of New Data

Corporate Strategy Presenta...

Clinical Trial Results

FDA Breakthrough Therapy De...

FDA Fast Track Designation ...

Appointment of Director

Financial Results Announcement

Settlement Agreement with L...

Presentation at BIO CEO and...

Presentation Announcement

Collaboration Announcement

External Links:

On April 22, 2026, SAB Biotherapeutics, Inc. announced the availability of a presentation and press release regarding the clinical trial results of their Phase 1 human anti-thymocyte biologic SAB-142. This event is significant for investors as it involves new developments in their product pipeline.

AI Assistant

SAB BIOTHERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.